This is a non-core endpoint: only basic statistics are computed.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
519870 |
1. Apply sex-specific ruleNone |
519870 |
2. Check conditionsNone |
519870 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
1 out of 7 registries used, show all original rules. |
22 |
4. Check minimum number of events
Min. number of events
3
|
22 |
5. Include endpointsNone |
22 |
6. Filter based on genotype QC (FinnGen only) |
22 |
Control definitions (FinnGen only)
- Control exclude
- RX_NSAID
Extra metadata
- First used in FinnGen datafreeze
- DF4
Similar endpoints
↥List of similar endpoints to
Butylpyrazolidines
based on the number of shared cases.
Similar with more cases:
- Anti-inflammatory and antirheumatic products, non-steroids
- Paracetamol or NSAID medication
- Any operation in hilmo
- Any prescribed medicine buy
- Any event in hilmo or specialist outpatient
Similar with less cases:
None
Case counts by codes
↥Summary Statistics
↥-FinRegistry-
This endpoint is excluded from FinRegistry analyses (omitted endpoint).
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 22 | 8 | 14 |
| Unadjusted period prevalence (%) | 0.01 | 0.00 | 0.01 |
| Median age at first event (years) | 46.95 | 41.83 | 49.88 |
-FinnGen-
Age distribution of first events
-FinnGen-
Year distribution of first events
-FinnGen-
Cumulative Incidence Function
Not a core endpoint, no data to show.
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
No data available
LabWAS
↥
OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
15
94
2.86
1.59
6.9
7.8
1.22
1.21
mmol/l
0.31
15
88
13
81
2.47
1.19
2.3
2.1
—
—
—
0
0
16
125
2.02
0.75
4.8
3.7
15.06
15.28
pmol/l
0.15
16
112
11
77
1.86
0.61
2.6
2.5
—
—
estimate
—
0
0
14
107
1.84
0.58
9.4
9.7
1.21
1.21
mmol/l
0.03
14
92
5
31
1.79
0.47
5.8
7.3
105.80
103.81
mmol/l
—
5
31
0
18
0.00
0.42
0.0
1.3
—
—
—
0
0
0
10
0.00
0.22
0.0
1.0
—
—
—
0
0
16
146
1.35
0.19
25.7
26.2
13.96
13.95
%
0.01
16
146
6
73
0.76
0.19
5.8
3.2
—
—
—
0
0
9
80
1.21
0.19
2.1
3.1
90.00
78.45
nmol/l
—
9
73
5
42
1.25
0.11
2.8
3.2
12.00
1898.65
ng/l
—
5
34
5
44
1.18
0.11
2.6
2.1
—
—
—
0
0
6
56
1.10
0.10
2.2
2.7
65.17
53.37
u/l
—
6
51
15
140
1.22
0.09
30.6
26.9
330.00
330.74
g/l
0.15
15
140
10
95
1.10
0.00
2.1
2.0
77.50
87.83
pmol/l
—
5
56
0
5
0.00
-0.00
0.0
1.8
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
8
0.00
-0.00
0.0
7.5
—
24.48
—
0
8
Mortality – FinRegistry
↥This endpoint is excluded from FinRegistry analyses (omitted endpoint).
Relationships between endpoints
↥Index endpoint: RX_BUTYLPYRA – Butylpyrazolidines
GWS hits: -
This endpoint is excluded from FinRegistry analyses (omitted endpoint).